Carl Morris
Overview
Explore the profile of Carl Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonnemann C, Belluscio B, Braun S, Morris C, Singh T, Muntoni F
N Engl J Med
. 2023 Jun;
388(24):2294-2296.
PMID: 37314712
No abstract available.
2.
Chamberlain J, Robb M, Braun S, Brown K, Danos O, Ganot A, et al.
Hum Gene Ther
. 2023 Jan;
34(9-10):404-415.
PMID: 36694468
Duchenne muscular dystrophy (DMD) is a serious, rare genetic disease, affecting primarily boys. It is caused by mutations in the gene and is characterized by progressive muscle degeneration that results...
3.
Measuring Greater Patient-Provider Continuity in a Clinic-First Family Medicine Residency Curriculum
Paul K, Hidaka B, Ford P, Morris C
Perm J
. 2022 Mar;
25.
PMID: 35348070
Introduction: Continuity is valued by patients, clinicians, and health systems for its association with higher-value care and satisfaction. Continuity is a commonly cited reason for entering primary care; however, it...
4.
Evans W, Shankaran M, Smith E, Morris C, Nyangau E, Bizieff A, et al.
J Physiol
. 2021 Sep;
599(23):5215-5227.
PMID: 34569076
Boys with Duchenne muscular dystrophy (DMD) experience a progressive loss of functional muscle mass, with fibrosis and lipid accumulation. Accurate evaluation of whole-body functional muscle mass (MM) in DMD patients...
5.
Demonbreun A, Fallon K, Oosterbaan C, Vaught L, Reiser N, Bogdanovic E, et al.
Sci Transl Med
. 2021 Sep;
13(610):eabf0376.
PMID: 34516828
Duchenne muscular dystrophy, like other muscular dystrophies, is a progressive disorder hallmarked by muscle degeneration, inflammation, and fibrosis. Latent transforming growth factor β (TGFβ) binding protein 4 (LTBP4) is an...
6.
Leung D, Bocchieri A, Ahlawat S, Jacobs M, Parekh V, Braverman V, et al.
Muscle Nerve
. 2021 May;
64(2):172-179.
PMID: 33961310
Introduction/aims: In this study we report the results of a phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab, a myostatin inhibitor, in patients with fukutin-related protein (FKRP)-associated limb-girdle muscular dystrophy....
7.
Peay H, Fischer R, Mange B, Paquin R, Smith E, Sadosky A, et al.
Mol Genet Genomic Med
. 2021 Mar;
9(5):e1664.
PMID: 33755338
Background: Gene therapy offers an etiologically targeted treatment for genetic disorders. Little is known about the acceptance of mortality risk among patients with progressive, fatal conditions. We assessed patients' and...
8.
Leung D, Bocchieri A, Ahlawat S, Jacobs M, Parekh V, Braverman V, et al.
BMC Neurol
. 2020 May;
20(1):196.
PMID: 32429923
Background: Pathogenic variants in the FKRP gene cause impaired glycosylation of α-dystroglycan in muscle, producing a limb-girdle muscular dystrophy with cardiomyopathy. Despite advances in understanding the pathophysiology of FKRP-associated myopathies,...
9.
Paquin R, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, et al.
Orphanet J Rare Dis
. 2019 May;
14(1):102.
PMID: 31072340
Purpose: Several gene therapy trials for Duchenne muscular dystrophy initiated in 2018. Trial decision making is complicated by non-curative, time-limited benefits; the progressive, fatal course; and high unmet needs. Here,...
10.
Peay H, Fischer R, Tzeng J, Hesterlee S, Morris C, Martin A, et al.
PLoS One
. 2019 May;
14(5):e0213649.
PMID: 31042754
Objectives: Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder that causes progressive weakness and early death. Gene therapy is an area of new therapeutic development. This qualitative study explored...